anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
After RFCA, and after follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will come to this group/stage (SAFE PAF-SND II). At this stage, the pacing mode and the lower rate of pacemaker will be set as VDD and 40 bpm respectively. If the patient can not tolerate, the the pacing mode and the lower rate of pacemaker will be set as DDD/DDDR and 60 bpm. If the patient has no symptom related to bradycardia, he/she will be followed up until the end of this study.
Participants enrolled in the nurse-led version of the Ned Virtual Clinic will be prompted to complete their PROs (EPIC-26 survey) and PSA/testosterone lab tests in accordance to their pre-specified follow-up surveillance protocol determined by the specialist. In addition, men will be asked to complete another set of PROs that will be monitored by a trained oncology nurse, in between their specialist visits.
The present invention relates generally to a method for preventing, inhibiting or otherwise reducing cell death. More particularly, the present invention contemplates a method for preventing, inhibiting or otherwise reducing neuronal cell death such as during neurodegenerative disease or following trauma. The method of the present invention is generally practiced by the administration, to a mammalian including a human subject, of an effective amount of an agent which blocks, retards or otherwise impairs ions from entering or passing through an ion channel. In one particular embodiment, the ion channel is a potassium (K) ion (K+) channel. The present invention further provides compositions comprising ion channel blockers and in particular K+ channel blockers. The compositions may also comprise other therapeutic agents such as agents which reduce levels of, or the activity of, a neurotrophin receptor. The present invention further provides methods for promoting cell survival by promoting intracellular cleavage of the neutrophil receptor by generating or introducing intracellular forms of the receptor such as by genetic or protein supplementation means. The present invention further provides a method for determining the likelihood of neurological cell degeneration by determining the level of function of K+ channels wherein an impaired ion channel is indicative of a reduced likelihood of neuronal cell apoptosis. Furthermore, the present invention provides antagonists of K+ channels, such as antagonists of molecules which mediate K+ channel activation via neurotrophin receptors or domains thereof.
Esophageal cancer is one of the most common malignant tumor and esophageal squamous cell carcinoma is the main pathological type of esophageal carcinoma in China. Among patients with advanced or metastatic esophageal squamous cell carcinoma, the addition of immunotherapy to chemotherapy, compared with placebo and chemotherapy, significantly improved overall survival and progression-free survival.Treatment of recurrent or metastatic esophageal squamous cell carcinoma is usually poor. New treatments were needed. Fruquintinib is an orally antiangiogenic agents, which target VEGFR1/2/3. A combination of Fruquintinib and s-1 for advanced or metastatic esophageal squamous cell carcinoma could be a novel therapy. Therefore, investigators initialize this phase II study to explore the safety of fruquintinib and S-1 combination treatment in ESCC patients with after failure in 1st-line immunotherapy.
PURPOSE: A composition for preventing or treating alopecia is provided to enhance catechin absorption rate. CONSTITUTION: A composition for preventing or treating alopecia contains extract of Thuja orientali, Polygoni multiflori Radix, Rosae rugosae Flos, or black pepper plant leaves as an active ingredient. The composition further contains saccahrides or acid. The catechin is epicatechin, catechin, epigallocatechin, gallocatechin, epicatechin-3-gallate, catechin-3-gallate, or gallocatechin-3-gallate. The saccharide is glucose, fructose, mannose, galactose, and ribose. The composition is used in the form of powder, liquid, tablet, capsule, or jelly.
Placebo will be self-administered with twice daily doses according to the Titration Period schedule for the first two weeks to the highest tolerable dose up to 4 mL twice daily. Patients receive placebo PO BID for up to 3 months. Patients also undergo blood sample collection on study.
Focused Ultrasound will be administered using medium frequency stimulation as condition 2. Stimulation will last 1-10 minutes.
Participants in this arm will have genotyping for CYP2D6 and OPRM1, however this information will not be provided to the physicians for treatment of the analgesic therapy but will be used for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).
Patients in experimental group will perform expiratory muscle training as home programme for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device. The intensity of training will been setted 30% of the maximal expiratory pressure level.
The invention relates to medicine composition for preventing and curing tumors, which effectively prevents and cures the tumors. The technical scheme includes that the medicine composition is mixed and prepared by from 2- methoxyestradiol (component a) and curcumin derivant (component b). The mole mixing ratio of the component a and the component b is 1:2, and the content range of the component a is 1-15 parts, and the content range of the component b is 2-30 parts. The component b is the mixture of one or more than two of curcumin, demethoxycurcumin and bisdethoxy curcumin which have equal mole ratios. The medicine composition is prepared into one of tablets, capsules, dripping pills, micro pills, oral liquid, freeze-drying preparation, injection, infusion solution, suppository, ointments, babu plaster and transdermal agent according to a conventional preparation method. The medicine composition is low in cost, has multi-target and multipurpose anti-tumor effects, is safe and reliable, effectively improves treatment compliances of patients, and plays an important role in preventing and curing the tumors to the greatest extent.
The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
A health promoting food composition of the present invention contains hormones having immune and intelligence enhancing effect, or those hormones in combination with anti-viral and/or anti-bacterial antibodies, and/or fructans. Thymic, adrenal and thyroid hormones are the main hormones in enhancing the immune function and in promoting intelligence development. The anti-viral antibodies are antibodies used against rotaviruses, respiratory syncynthial viruses, influenza viruses, and parainfluenza viruses. Fructans that may be used are oligofructoses and inulin. The health promoting food may be used to: (1) increase the immune function and enhance mental development of a mammal; (2) inhibit viral and/or bacterial infection in a mammal; and (3) selectively stimulate colon bifidobacteria and lactobacilli in a mammal. The combination of those hormones, fructans, and viral antibodies in a nutritional product may be used to provide overall health protection for a mammal. A method of production and use of the health-promoting food is also provided.
Peptide (I) comprising a fragment of neurotensin receptor 3 (NTSR3) is a NTSR3 ligand : Peptide of formula (I) is a neurotensin receptor 3 (NTSR3) ligand. Ala Pro Leu Pro Arg Trp Ser Gly Pro Ile Gly Val Ser Trp Gly Leu Arg (I). Independent claims are also included for: (1) nucleic acid coding for (I); (2) vector and host cell containing the nucleic acid; (3) producing (I) by transfecting a host cell with a nucleic acid as above or transforming a host cell with a vector as above and culturing the cell. ACTIVITY : Antidepressant; Antiinflammatory; Analgesic. Test details are described but no results for the compound of the claims are given. MECHANISM OF ACTION : Neurotensin receptor 3 ligand.
Objective: To develop a prediction tool for 6-year incident risk of frailty among Chinese older adults aged 65 years or above. Methods: Data from the Chinese Longitudinal Healthy Longevity Survey from 2002 to 2018 was used, including 13 676 older adults aged 65 years or above who were free of frailty at baseline. Key predictors of frailty were identified via the least absolute shrinkage and selection operator (LASSO) method, and were thereafter used to predict the incident frailty based on the Cox proportional hazards regression model. The model was internally validated by 2 000 Bootstrap resamples and evaluated for the performance of discrimination and calibration using the area under the receiver operating characteristic curve (AUC) and calibration curve, respectively. The net benefit of the developed prediction tool was evaluated by decision-curve analysis. Results: The M(Q1, Q3) age and follow-up time of the participants were 81.0 (71.0, 90.0) years and 6.0 (4.1, 9.2) years, respectively. A total of 4 126 older persons (30.2%) were recorded with frailty incidents during the follow-up, with the corresponding incidence density of 41.8/1 000 person-years. A total of 15 key predictors of frailty were selected by LASSO, namely, age, sex, race, education years, meat consumption, tea drinking, performing housework, raising domestic animals, playing cards or mahjong, and baseline status of visual function, activities of the daily living score, instrumental activities of the daily living score, hypertension, heart disease, and self-rated health. The prediction model was internally validated with an AUC of 0.802, with the max Youden's index of 0.467 at a risk threshold of 19.0%. The calibration curve showed high consistency between predicted probabilities and observed proportions of frailty events. The decision curve indicated that higher net benefits could be obtained via the prediction model than did strategies based on intervention in all or none participants for any risk threshold less than 59%, and the model-based net benefit was estimated to be 0.10 at a risk threshold of 19.0%. Conclusions: The herein developed 6-year incident risk prediction model of frailty, based on easily accessible questionnaires and physical examination variables, has good predictive performance. It has application potential in identifying populations at high risk of incident frailty.
PURPOSE: A solvent substitution method of superparamagnetic nanoparticles using branched polyethylene glycol is provided to effectively substitute superparamagnetic nanoparticles into a solution and to be used as a cell marker and magnetic resonance imaging contrast. CONSTITUTION: A solvent substitution method of superparamagnetic nanoparticles comprises: a step of injecting branched polyethylene glycol into a first solvent containing the superparamagnetic nanoparticles; and a step of removing the first solvent and adding a second solvent. The branched polyethylene glycol is denoted by chemical formula 1. The first solvent is chloroform or hexane. The second solvent is an aqueous solution including water, distilled water, saline solution, or water soluble biological buffer solution. The buffer solution is HEPES[4-2-hydroxyethyl-1-piperazineethanesulfonic acid], MES[2-(N-morpholino)ethanesulfonic acid], MOPS, Tris(tris(hydroxymethyl)methylamine), or glycine. [Reference numerals] (AA) Branch 1; (BB) Branch 2; (CC) Branch 3; (DD) Branch 4; (EE) Branch m
AIM: Bile acids (BAs) are implicated in the pathogenesis of several metabolic syndrome-related diseases, including insulin resistance (IR) and type 2 diabetes (T2D). It has been reported that IR and T2D are associated with an increased ratio of 12α/non-12α-hydroxylated BAs in the circulating BA pool. It is, however, unknown whether the improvement of insulin sensitivity inversely affects BA composition in humans. Therefore, we assessed whether lifestyle-induced weight loss induces changes in BA metabolism in people with obesity, with or without T2D, and if these changes are associated with metabolic parameters.
MATERIALS AND METHODS: Individual BAs and C4 were quantified by ultra-high-performance liquid chromatography-tandem mass spectrometry in plasma samples collected from two cohorts of people with obesity (OB) and with T2D and obesity (T2D), before and after a lifestyle intervention.
RESULTS: Lifestyle-induced weight loss improved glycaemic control in both cohorts, with plasma BA concentrations not affected by the lifestyle interventions. The ratio of 12α/non-12α-hydroxylated BAs remained unchanged in OB (p = .178) and even slightly increased upon intervention in T2D (p = .0147). Plasma C4 levels were unaffected in OB participants (p = .20) but significantly reduced in T2D after intervention (p = .0003). There were no significant correlations between the ratio of 12α/non-12α-hydroxylated BAs and glucose, insulin, or homeostatic model assessment-IR, nor in plasma triglycerides, low-density lipoprotein cholesterol, lipoprotein (a) in the T2D cohort.
CONCLUSIONS: Lifestyle-induced weight loss did improve glycaemic control but did not affect BA concentrations. Improvements in insulin sensitivity were not associated with changes in BA parameters in people with obesity, with or without T2D.
INTRODUCTION AND OBJECTIVES: Blood glucose fluctuates severely in the diabetes (DM) and tumor microenvironment. Our previous works have found Hepatitis B virus X protein (HBx) differentially regulated metastasis and apoptosis of hepatoma cells depending on glucose concentration. We here aimed to explore whether HBx played dual roles in the angiogenesis of hepatocellular carcinoma varying on different glucose levels.
MATERIALS AND METHODS: We collected conditioned medium from HBx-overexpressing cells cultured with two solubilities of glucose, and then applied to EA.hy926 cells. Alternatively, a co-culture cell system was established with hepatoma cells and EA.hy926 cells. We analyzed the angiogenesis of EA.hy926 cells with CCK8, wound-healing, transwell-migartion and tube formation experiment. ELISA was conducted to detect the secretion levels of angiogenesis-related factors. siRNAs were used to detect the P53-VEGF axis.
RESULTS: HBx expressed in hepatoma cells suppressed VEGF secretion, and subsequently inhibited the proliferation, migration and tube formation of EA.hy926 cells in a high glucose condition, while attenuating these in the lower glucose condition. Furthermore, the p53-VEGF axis was required for the dual role of HBx in angiogenesis. Additionally, HBx mainly regulated the nuclear p53.
CONCLUSIONS: These data suggest that the dual roles of HBx confer hepatoma cells to remain in a glucose-rich environment and escape from the glucose-low milieu through tumor vessels, promoting liver tumor progression overall. We exclusively revealed the dual role of HBx on the angiogenesis of liver tumors, which may shed new light on the mechanism and management strategy of HBV- and DM-related hepatocellular carcinoma.
In the collection of Mobile Application data, they will be asked to fill out the forms.The mobile application will be introduced, the application will be downloaded from the virtual market (Google Play Store or App Store) to the phone, login will be provided by giving a user name and password, and how to use the application will be explained. Participants will be asked to provide nursing care using this application once a week for 3 months. Nursing Diagnosis Perception Scale with nurses at the end of the 1st month and at the end of the 3rd month; " MıssCare" Detection Questionnaire in the Neonatal Intensive Care Unit; System Availability Scale will be applied.
The invention relates to novel compositions and to novel methods for the administration of compositions to a patient or to cells in vitro for the treatment of human disorders. In one embodiment, compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia and other blood disorders. In another embodiment, compositions contain an inducing agent and an anti-viral agent.  The inducing agent induces the expression of a cellular or viral product, such as viral thymidine kinase, increasing the sensitivity of proliferating cells to the anti-viral agent. Typical anti-viral agents include nucleoside analogs such as ganciclovir that inhibit viral replication. Methods involve administration of therapeutically effective amounts of the inducing agent with the anti-viral agent to destroy virus-infected cells. Viral infections that can be treated include infections by herpes viruses such as Kaposi's--associated herpes virus and Epstein-Barr virus, HIV infections and HTLV infections. These compositions and methods are particularly effective against episomal and latent infections in proliferating cells. The invention also relates to novel methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies such as viral-induced tumors, other forms of neoplasia and for expansion of cells for hematopoietic transplantation.
Sexual minority individuals have a markedly elevated risk of depression compared to heterosexuals. We examined early threats to social safety and chronically elevated inflammation as mechanisms contributing to this disparity in depression symptoms, and compared the relative strength of the co-occurrence between chronic inflammation and depression symptoms for sexual minorities versus heterosexuals. To do so, we analyzed data from a prospective cohort of sexual minority and heterosexual young adults (n = 595), recruited from a nationally representative sample, that included assessments of early threats to social safety in the form of adverse childhood interpersonal events, three biomarkers of inflammation (i.e., CRP, IL-6, TNF-α) measured at two time points, and depression symptoms over four years. In pre-registered analyses, we found that sexual minorities experienced more adverse childhood interpersonal events, were more likely to display chronically elevated inflammation, and reported more severe depression symptoms than heterosexuals. Adverse childhood interpersonal events and chronically elevated inflammation explained approximately 23 % of the total effect of the association between sexual orientation and depression symptom severity. Further, there was an increased coupling of chronically elevated inflammation and depression symptoms among sexual minorities compared to heterosexuals. These results provide novel longitudinal, population-based evidence for the role of chronically elevated inflammation in linking threats to social safety during childhood with depression symptom severity in young adulthood, consistent with the primary tenets of the social signal transduction theory of depression. Our study extends this theory to the population level by finding that members of a stigmatized population (i.e., sexual minorities) experience a greater risk of depression because of their greater exposure to adverse childhood interpersonal events and the subsequent link to chronic inflammation, highlighting potential biopsychosocial intervention targets.
The global increase in antibiotic consumption is related to increased adverse effects, such as antibiotic-associated diarrhea (AAD). This study investigated the chemical properties of Zingiber officinale Rosc (ZO) extract and its ameliorative effects using a lincomycin-induced AAD mouse model. Intestinal tissues were evaluated for the expression of lysozyme, claudin-1, and α-defensin-1, which are associated with intestinal homeostasis. The cecum was analyzed to assess the concentration of short-chain fatty acids (SCFAs). The chemical properties analysis of ZO extracts revealed the levels of total neutral sugars, acidic sugars, proteins, and polyphenols to be 86.4%, 8.8%, 4.0%, and 0.8%, respectively. Furthermore, the monosaccharide composition of ZO was determined to include glucose (97.3%) and galactose (2.7%). ZO extract administration ameliorated the impact of AAD and associated weight loss, and water intake also returned to normal. Moreover, treatment with ZO extract restored the expression levels of lysozyme, α-defensin-1, and claudin-1 to normal levels. The decreased SCFA levels due to induced AAD showed a return to normal levels. The results indicate that ZO extract improved AAD, strengthened the intestinal barrier, and normalized SCFA levels, showing that ZO extract possesses intestinal-function strengthening effects.
ABSTRACT         The specification describes a process for producing liquid-loaded powders which are capable of releasing their liquid load when subjected to shearing forces.  A cellulosic polymer and a liquid load are dissolved in a polar solvent to form a solution.  The solvent is then dispersively evaporated from the solution to form a liquid-loaded powder. Dispersive evaporation of the solvent in a spray drying tower is described.  Cellulosic polymers exemplified in the specification include cellulose triacetate, an ethyl cellulose and a cellulose propionate.   Solvents exemplified include methylene chloride, ethyl acetate and acetone.  Uses of the liquid-loaded powder described include a carrier for fragrances used in toilet soap formulation, a sunscreen formulation in powder form, an insect repellent in powder form, a baby oil and a moisturizer in powder form.
The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invent ion concerns methods of treating estrogen-dependent conditions such as endom etrial hyperplasia and endometrial cancer in a female undergoing estrogen an d/or selective estrogen receptor modulator (SERM) therapy. The instant inven tion is also relevant to the suppression of endometrial proliferation. The i nstant invention is also relevant to the treatment of pain associated with e ndometriosis. The compositions for practicing the methods, comprising proges terone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor mo dulators for practicing disclosed methods of treatment.